Falcon Point Capital LLC Decreases Position in Maximus, Inc. (MMS)
Falcon Point Capital LLC reduced its stake in shares of Maximus, Inc. (NYSE:MMS) by 3.4% during the second quarter, Holdings Channel reports. The institutional investor owned 219,648 shares of the health services provider’s stock after selling 7,839 shares during the period. Maximus accounts for approximately 1.9% of Falcon Point Capital LLC’s investment portfolio, making the stock its 24th largest position. Falcon Point Capital LLC’s holdings in Maximus were worth $13,757,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of the stock. BlackRock Inc. boosted its stake in Maximus by 22,491.0% in the first quarter. BlackRock Inc. now owns 6,503,511 shares of the health services provider’s stock valued at $404,518,000 after buying an additional 6,474,723 shares in the last quarter. Vanguard Group Inc. boosted its stake in Maximus by 8.0% in the first quarter. Vanguard Group Inc. now owns 5,538,187 shares of the health services provider’s stock valued at $344,476,000 after buying an additional 411,521 shares in the last quarter. William Blair Investment Management LLC boosted its stake in Maximus by 14.7% in the first quarter. William Blair Investment Management LLC now owns 4,416,279 shares of the health services provider’s stock valued at $274,693,000 after buying an additional 566,292 shares in the last quarter. Victory Capital Management Inc. boosted its position in shares of Maximus by 14.9% in the first quarter. Victory Capital Management Inc. now owns 2,856,080 shares of the health services provider’s stock valued at $177,648,000 after buying an additional 369,794 shares during the period. Finally, State Street Corp boosted its position in shares of Maximus by 2.5% in the first quarter. State Street Corp now owns 2,066,226 shares of the health services provider’s stock valued at $128,517,000 after buying an additional 50,670 shares during the period. 97.89% of the stock is owned by institutional investors.
Maximus, Inc. (MMS) opened at 60.83 on Friday. Maximus, Inc. has a one year low of $43.69 and a one year high of $64.97. The company has a market capitalization of $3.95 billion, a PE ratio of 19.50 and a beta of 1.39. The firm’s 50 day moving average price is $61.19 and its 200-day moving average price is $60.86.
Maximus (NYSE:MMS) last released its earnings results on Thursday, August 3rd. The health services provider reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.76 by $0.03. The firm had revenue of $600.40 million during the quarter, compared to the consensus estimate of $614.12 million. Maximus had a return on equity of 25.08% and a net margin of 8.43%. The company’s revenue was down 2.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.79 EPS. Equities analysts forecast that Maximus, Inc. will post $3.12 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, August 31st. Stockholders of record on Tuesday, August 15th will be given a dividend of $0.045 per share. The ex-dividend date of this dividend is Friday, August 11th. This represents a $0.18 dividend on an annualized basis and a dividend yield of 0.30%. Maximus’s payout ratio is 5.73%.
Several research analysts recently commented on the company. Zacks Investment Research cut Maximus from a “buy” rating to a “hold” rating in a research report on Wednesday. Maxim Group set a $66.00 target price on Maximus and gave the stock a “hold” rating in a research report on Thursday, August 3rd. BidaskClub cut Maximus from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Canaccord Genuity cut Maximus from a “buy” rating to a “hold” rating and set a $62.00 target price for the company. in a research report on Tuesday, July 4th. Finally, KeyCorp reaffirmed a “sector weight” rating on shares of Maximus in a research report on Thursday, May 25th. One equities research analyst has rated the stock with a sell rating and eight have issued a hold rating to the stock. The stock has an average rating of “Hold” and an average price target of $62.17.
In other news, CEO Richard A. Montoni sold 30,000 shares of the company’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $62.81, for a total transaction of $1,884,300.00. Following the completion of the sale, the chief executive officer now directly owns 584,114 shares in the company, valued at approximately $36,688,200.34. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, President Bruce Caswell sold 8,000 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $59.83, for a total value of $478,640.00. Following the sale, the president now owns 35,904 shares of the company’s stock, valued at $2,148,136.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 99,439 shares of company stock valued at $6,215,325. Corporate insiders own 3.10% of the company’s stock.
Maximus Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
Want to see what other hedge funds are holding MMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maximus, Inc. (NYSE:MMS).
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.